首页> 美国卫生研究院文献>Clinical Pharmacology : Advances and Applications >Lidocaine 5 patch for localized neuropathic pain: progress for the patient a new approach for the physician
【2h】

Lidocaine 5 patch for localized neuropathic pain: progress for the patient a new approach for the physician

机译:5%利多卡因贴剂用于局部神经性疼痛:患者的进步是医师的新方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Neuropathic pain (NeP) syndromes remain a difficult-to-treat medical entity. Despite a growing number of pharmacological and invasive analgesic therapies the results remain less than optimal because of insufficient analgesic efficacy and/or occurrence of pronounced side effects. Current guidelines propose the use of multimodal and balanced pharmacological therapies, focused on the underlying pathophysiological mechanisms (mechanistic approach). Lidocaine 5% patches are a new treatment option currently licensed for the treatment of postherpetic neuralgia. However, these patches can also be used for the treatment of different types of superficial NeP syndromes, such as diabetic polyneuropathy. Their therapeutic success, however, largely depends on the correct identification of appropriate patients and pain syndromes. This manuscript outlines the correct identification of patients and proper use of these patches in order to ensure as much as possible the therapeutic efficacy of this new treatment option.
机译:神经性疼痛(NeP)综合征仍然是很难治疗的医学实体。尽管药理学和侵入性止痛药的数量不断增长,但由于止痛药效力不足和/或出现明显的副作用,结果仍达不到最佳效果。当前的指南建议使用多模式和平衡的药理疗法,重点是潜在的病理生理机制(机械方法)。 5%的利多卡因贴剂是目前许可用于治疗带状疱疹后神经痛的新治疗选择。但是,这些贴片也可以用于治疗不同类型的浅表NeP综合征,例如糖尿病性多发性神经病。然而,它们的治疗成功很大程度上取决于对适当患者和疼痛综合征的正确识别。该手稿概述了对患者的正确识别以及对这些贴剂的正确使用,以尽可能确保这种新治疗方案的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号